FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

W Kievit

Research Profile

Disorders

Chemicals & Drugs

Geographic Areas

Netherlands

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Sanne A A van Dartel; Mart A F van de Laar; Herman L M Brus; Ellen A J Dutmer; Jaap Fransen; Nella M Houtman; W Kievit; Piet L C M van Riel
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Sanne A A van Dartel; Mart A F J van de Laar; H Visser; Alfons A den Broeder; Marcel Flendrie; Jaap Fransen; A Hartkamp; W Kievit; Piet L C M van Riel
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Paula P M van Lümig; Jan B M Boezeman; Rieke J B Driessen; W Kievit; Peter C M van de Kerkhof; Elke M G J de Jong
Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of W Kievit (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sanne A A van Dartel; Mart A F van de Laar; Herman L M Brus; Ellen A J Dutmer; Jaap Fransen; Nella M Houtman; W Kievit; Piet L C M van Riel
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Rheumatology (Oxford, England) 2013;52(6):1052-7.
2013: Sanne A A van Dartel; Mart A F J van de Laar; H Visser; Alfons A den Broeder; Marcel Flendrie; Jaap Fransen; A Hartkamp; W Kievit; Piet L C M van Riel
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Annals of the rheumatic diseases 2013;72(6):895-900.
2013: Paula P M van Lümig; Jan B M Boezeman; Rieke J B Driessen; W Kievit; Peter C M van de Kerkhof; Elke M G J de Jong
Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice.
Journal of the American Academy of Dermatology 2013;68(1):57-63.
2012: Aatke van der Maas; Piet L van Riel; W Kievit; Bart J F van den Bemt; Frank H J van den Hoogen; Alfons A den Broeder
Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study.
Annals of the rheumatic diseases 2012;71(11):1849-54.
2012: Yvonne M R de Punder; Jaap Fransen; Pieternella M Houtman; W Kievit; Mart A F J van de Laar; Henk Visser; Piet L C M van Riel
The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Rheumatology (Oxford, England) 2012;51(9):1610-7.
2012: Erik J M Toonen; Simon V van Reijmersdal; Piet L C M van Riel; Joris A Veltman; Alfons A den Broeder; A M M Eijsbouts; Barbara Franke; Christian Gilissen; W Kievit; Timothy R D J Radstake; Hans Scheffer; Pilar Barrera; Marieke Coenen
Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis.
PloS one 2012;7(3):e33199.
2011: Marlies Blom; Amanda J W Branten; Herman L M Brus; Alfons A den Broeder; A Rogier T Donders; Tim Jansen; W Kievit; Ina Kuper; Vincent H H P Straten; M A F J van de Laar; Henk Visser; Piet L C M van Riel
Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
The Journal of rheumatology 2011;38(11):2355-61.
2011: L T C van Hulst; P L C M van Riel; W Kievit; R van Bommel; L Fraenkel
Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.
Arthritis care & research 2011;63(10):1407-14.
2011: Lydia G Schipper; Mart A van der Laar; Eddy M M Adang; Alfons A den Broeder; Jaap Fransen; W Kievit; Piet L C M van Riel
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Rheumatology (Oxford, England) 2011;50(7):1320-30.
2011: Hilbert S de Vries; Martijn G H Van Oijen; Rieke J B Driessen; Elke M G J de Jong; Marjonne C W Creemers; W Kievit; Dirk J de Jong
Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.
British journal of clinical pharmacology 2011;71(1):7-19.
2011: W Kievit; Jaap Fransen; Eddy M M Adang; Alfons A den Broeder; Hein J Bernelot Moens; Henk Visser; M A F J van de Laar; Piet L C M van Riel
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.
Rheumatology (Oxford, England) 2011;50(1):196-203.
2010: M Blom; W Kievit; H H Kuper; Tim Jansen; H Visser; Alfons A den Broeder; H L M Brus; M A F J van de Laar; P L C M van Riel
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.
Arthritis care & research 2010;62(9):1335-41.
2010: W Kievit; Jos Hendrikx; Peep F M Stalmeier; M A F J van de Laar; Piet L C M Van Riel; Eddy M M Adang
The relationship between change in subjective outcome and change in disease: a potential paradox.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2010;19(7):985-94.
2010: W Kievit; Laura van Hulst; Piet van Riel; Liana Fraenkel
Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis.
Arthritis care & research 2010;62(6):842-7.
2010: Marieke Coenen; Christian Enevold; Pilar Barrera; Mascha M V A P Schijvenaars; Erik J M Toonen; Hans Scheffer; Leonid Padyukov; Alf Kastbom; Lars Klareskog; Anne Barton; W Kievit; Maarten J Rood; Tim L Jansen; Dorine W Swinkels; Piet L C M van Riel; Barbara Franke; Klaus Bendtzen; Timothy R D J Radstake
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome.
PloS one 2010;5(12):e14326.
2010: Chin Teck Ng; B J Radovits; W Kievit; Jaap Fransen; P L C M van Riel; O FitzGerald; douglas veale; B Bresnihan
Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing.
Annals of the rheumatic diseases 2010;69(1):313-4.
2009: Marlies Blom; W Kievit; Jaap Fransen; Ina H Kuper; Alfons A den Broeder; Carla M A De Gendt; Tim Jansen; Herman L M Brus; M A F J van de Laar; Piet L C M van Riel
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
The Journal of rheumatology 2009;36(10):2171-7.
2009: B J Radovits; W Kievit; Jaap Fransen; M A F J van de Laar; Tim Jansen; P L C M van Riel; R F J M Laan
Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
Annals of the rheumatic diseases 2009;68(9):1470-3.
2009: W Kievit; Jaap Fransen; Eddy M M Adang; H H Kuper; Tim Jansen; C M A De Gendt; D J R A M De Rooij; H L M Brus; M A F J van de Laar; P C L M Van Riel
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
Annals of the rheumatic diseases 2009;68(6):844-9.
2009: Beáta J Radovits; W Kievit; R F J M Laan
Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.
Drugs & aging 2009;26(8):647-64.
2008: W Kievit; Eddy M M Adang; Jaap Fransen; H H Kuper; M A F J van de Laar; Tim Jansen; C M A De Gendt; D-J R A M De Rooij; H L M Brus; P C M Van Oijen; P C L M Van Riel
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
Annals of the rheumatic diseases 2008;67(9):1229-34.
2008: Erik J M Toonen; Marieke Coenen; W Kievit; Jaap Fransen; A M M Eijsbouts; Hans Scheffer; Timothy Radstake; M C W Creemers; D-J R A M de Rooij; P L C M van Riel; B Franke; Pilar Barrera
The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.
Annals of the rheumatic diseases 2008;67(8):1174-7.
2007: W Kievit; Jaap Fransen; A J M Oerlemans; H H Kuper; M A F J van der Laar; D J R A M de Rooij; C M A De Gendt; K H Ronday; Tim Jansen; P C M van Oijen; H L M Brus; Eddy M M Adang; P L C M van Riel
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
Annals of the rheumatic diseases 2007;66(11):1473-8.
2006: W Kievit; Paco M J Welsing; Eddy M M Adang; A M Eijsbouts; Paul Krabbe; P L C M van Riel
Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health.
Arthritis and rheumatism 2006;55(5):745-50.
2005: W Kievit; Marieke J Bolster; Gert Jan van der Wilt; Peter Bult; Frederik B J M Thunnissen; J Meijer; Luc J A Strobbe; J H G Klinkenbijl; Theo Wobbes; Eddy M M Adang; Louk V A M Beex; Vivianne C G Tjan-Heijnen
Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(12):1874-81.
2005: J H F M de Bruin; W Kievit; M J L Ligtenberg; Fokko M Nagengast; Eddy M M Adang; T J M Ruers; J H Kleibeuker; Rolf Sijmons; J H J M van Krieken; Nicoline Hoogerbrugge
[More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability].
Nederlands tijdschrift voor geneeskunde 2005;149(32):1792-8.
2005: Paco M J Welsing; W Kievit; Roland F J M Laan; Johan L Severens
Quality of life and costs for different treatment strategies for rheumatoid arthritis.
Expert review of pharmacoeconomics & outcomes research 2005;5(4):395-410.
2005: W Kievit; J H F M de Bruin; Eddy M M Adang; J L Severens; J H Kleibeuker; Rolf Sijmons; T J M Ruers; Fokko M Nagengast; H F A Vasen; J H J M van Krieken; M J L Ligtenberg; Nicoline Hoogerbrugge
Cost effectiveness of a new strategy to identify HNPCC patients.
Gut 2005;54(1):97-102.
2004: W Kievit; J H F M de Bruin; Eddy M M Adang; M J L Ligtenberg; Fokko M Nagengast; J H J M van Krieken; Nicoline Hoogerbrugge
Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis.
Clinical genetics 2004;65(4):308-16.